Vontobel Holding Ltd. Invests $222,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Vontobel Holding Ltd. purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 9,500 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other hedge funds also recently added to or reduced their stakes in the business. NBC Securities Inc. raised its position in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics in the 2nd quarter valued at about $35,000. ORG Wealth Partners LLC acquired a new position in TG Therapeutics in the third quarter valued at about $53,000. DekaBank Deutsche Girozentrale purchased a new position in TG Therapeutics during the first quarter worth about $58,000. Finally, nVerses Capital LLC increased its position in shares of TG Therapeutics by 34.9% during the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,500 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $23.13 on Thursday. The company’s 50 day moving average is $23.32 and its two-hundred day moving average is $19.53. The firm has a market cap of $3.57 billion, a PE ratio of 102.70 and a beta of 2.21. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. TG Therapeutics, Inc. has a 52-week low of $6.77 and a 52-week high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $65.92 million. During the same period last year, the firm earned ($0.34) earnings per share. The company’s revenue for the quarter was up 357.0% compared to the same quarter last year. On average, research analysts expect that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on TGTX. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. Finally, B. Riley lifted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, TG Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $31.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.